Nymox Pharmaceutical Corporation
NYMXF
$0.1364
$0.026424.00%
OTC PK
| 12/31/2023 | 12/31/2023 | 09/30/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Net Income | -412.64% | -412.64% | 6.67% | 6.67% | 19.97% |
| Total Depreciation and Amortization | -71.79% | -70.92% | -25.40% | -23.10% | -1.73% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 43,741.67% | 37,865.98% | -70.87% | -74.77% | -53.30% |
| Change in Net Operating Assets | 357.71% | 357.71% | -351.35% | -351.35% | -58.89% |
| Cash from Operations | 28.98% | 28.98% | -38.94% | -38.94% | 8.00% |
| Capital Expenditure | -- | -- | -- | -- | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | 100.00% |
| Total Debt Issued | 200.00% | 200.00% | -66.67% | -66.67% | -- |
| Total Debt Repaid | 2,404.65% | 195.01% | -1,638.33% | 28.33% | 1.64% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -26.18% | -26.18% | 74.93% | 74.93% | 1,231.15% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 89.29% | 89.29% | 74.43% | 74.43% | 79.18% |